

## Measurement Year 2018 (MY 2018) Value Based P4P and Medicare Stars Measure Set and Summary of Changes

This document highlights any changes from the (MY) 2017 Value Based P4P and Medicare Stars Measure Set and updates from the [2017 Call for Public Comment](#) document.

### ***Program and Policy Updates***

---

- *None.*

### ***MY 2018 VBP4P Measure Adoptions***

---

Based on MY 2017 testing, the following measures will be added to the MY 2018 Commercial VBP4P measure set as baseline measures.

**Note:** *IHA aligns with measure specification updates from measure stewards when possible; updated specifications will be included in the MY 2018 VBP4P Manual September 1, 2018.*

#### ***Use of Opioids at High Dosage (UOD)***

This HEDIS measure captures the rate per 1,000 (for members 18 years and older) receiving prescription opioids for  $\geq 15$  days during the measurement year at a high dosage (average morphine equivalent dose [MED]  $> 120$  mg). The current specification for this measure can be found on page 202 of the [MY 2017 VBP4P Manual](#).

The *UOD* measure was included as a testing measure in MY 2017 and was specifically developed in response to an increased focus on lowering opioid-related morbidity and mortality nationally and across providers, health plans, purchasers, and policymakers in California.

#### ***Concurrent Use of Opioids and Benzodiazepines (COB)***

This PQA measure captures the percentage of members 18 years of age and older with concurrent use of prescription opioids and benzodiazepines during the treatment period. The current specification for this measure can be found on page 207 of the [MY 2017 VBP4P Manual](#).

The *COB* measure was included as a testing measure in MY 2017 and was specifically developed in response to an increased focus on lowering opioid-related morbidity and mortality nationally and across providers, health plans, purchasers, and policymakers in California.

#### ***Diabetes Care (CDC): Eye Exam***

The HEDIS *CDC: Eye Exam* measure was included as a testing measure in MY 2017. This measure will be added to the Commercial product line in alignment with HEDIS.

The current specification for this measure can be found on page 64 of the [MY 2017 VBP4P Manual](#).

## ***MY 2018 VBP4P Testing Measures***

---

Testing measures will be announced as part of IHA public comment on September 1, 2018.

## ***MY 2018 Medicare Stars Measure Adoptions***

---

The following measures were included as baseline measures in MY 2017 and will be added to the Medicare Stars measure set for public reporting in MY 2018.

**Note:** IHA aligns with measure specification updates from measure stewards when possible; updated specifications will be included in the MY 2018 VBP4P Manual September 1, 2018.

### ***Statin Therapy for Patients With Cardiovascular Disease (SPC)***

This HEDIS measure captures the percentage of males 21–75 years of age and females 40–75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and received statin therapy and attained a statin adherence of 80%. The current specification for this measure can be found on page 51 of the [MY 2017 VBP4P Manual](#).

The first rate – *Received Statin Therapy* – will be used for public reporting and payment; the second rate – *Statin Adherence 80%* -- will be used for information only.

### ***Statin Use in Persons with Diabetes (SUPD)***

This PQA measure captures the percentage of patients ages 40–75 years who were dispensed a medication for diabetes that receive a statin medication. The current specification for this measure can be found on page 78 of the [MY 2017 VBP4P Manual](#).

The SUPD measure was added by CMS to the star rating system for health plans.

## ***MY 2018 Medicare Stars Measure Removals***

---

### ***Annual monitoring for Patients on Persistent Medications: ACE/ARB and Diuretics (MPM)***

The HEDIS measure captures the percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year.

- Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).
- Annual monitoring for members on diuretics.
- Total rate (the sum of the two numerators divided by the sum of the two denominators).

The current specification for this measure can be found on page 42 of [MY 2017 VBP4P Manual](#).

The MPM measure has been collected for over 10 years and shows high performance and limited variation across all POs participating in VBP4P. Based on the diminished opportunity for further performance improvement and desire to reduce participant reporting burdens, this measure will be retired from the measure set beginning in MY 2018.

### *Diabetes Care: Two HbA1c Tests*

The *CDC: Two HbA1c tests* measure has very limited use in other national performance measurement programs. Value Based P4P committees voted to retire the *CDC: Two HbA1c* measure to reduce misalignment with other measurement programs and to place further emphasis on the related intermediate outcome measures for diabetes care.

The current specification for this measure can be found on page 64 of the [MY 2017 VBP4P Manual](#).

### ***MY 2018 Medicare Stars Testing Measures***

---

Testing measures will be announced as part of IHA public comment on September 1, 2018 based on changes made by the Centers for Medicaid and Medicare Services to their Medicare Advantage star rating system.

### ***MY 2018 Commercial P4P Advancing Care Information Domain Changes***

---

- *None.*